platoseedplatoseed
YourChoice therapeutics is revolutionizing the contraceptive market…
YourChoice Therapeutics is revolutionizing the global contraceptive market. Our vision is to develop non-hormonal contraceptives to provide both women and men with birth control options that lack the associated risks of hormone-based options but are equally effective. Traditionally, it has been the women’s financial and health burden to have a contraceptive in place. Our first goal is therefore to bring a novel non-hormonal, on-demand and low cost female contraceptive to the market that will substantially improve their quality of life and well-being. Our second goal is to develop the first ever non-surgical and highly effective non-hormonal contraceptive for men. Currently, male contraception is limited to two main options – vasectomy or condoms. Having such options available to both women and men will globally allow for much better family planning, reduce the number of unwanted pregnancies including abortions and therefore reduce costs and ensure contraceptive health and well-being.
YourChoice Therapeutics is developing YCT-529, the first oral, non-hormonal male contraceptive, currently in Phase 2 trials. The program focuses on blocking the retinoic acid receptor alpha to reversibly suppress sperm production. They publish research and sponsor clinical studies while engaging investors and media coverage.
YCT-529 is an oral, non-hormonal investigational agent that selectively antagonizes the retinoic acid receptor-alpha (RAR-alpha) to suppress sperm production. The company sponsors and collaborates on clinical studies to evaluate safety, tolerability, and pharmacokinetics, with ongoing Phase 2 trials. It is positioned as a daily pill in development for male contraception, with preclinical data showing reversibility upon stopping treatment.
Who it’s for: Men seeking a non-hormonal, oral contraceptive option; researchers and clinicians in male contraception; investors interested in biotech and gender-equity in contraception
active clinical development (Phase 2), research publications, investor materials access, media coverage
The first test designed to prevent birth control side effects
Legacy helps you test, improve, and freeze your sperm
